BR112017005744A2 - sistema de genética reversa para vírus pichinde e método de uso - Google Patents

sistema de genética reversa para vírus pichinde e método de uso

Info

Publication number
BR112017005744A2
BR112017005744A2 BR112017005744A BR112017005744A BR112017005744A2 BR 112017005744 A2 BR112017005744 A2 BR 112017005744A2 BR 112017005744 A BR112017005744 A BR 112017005744A BR 112017005744 A BR112017005744 A BR 112017005744A BR 112017005744 A2 BR112017005744 A2 BR 112017005744A2
Authority
BR
Brazil
Prior art keywords
coding region
reverse genetics
region encoding
genetics system
pichinde virus
Prior art date
Application number
BR112017005744A
Other languages
English (en)
Other versions
BR112017005744B1 (pt
Inventor
Hinh Ly
Liang Yuying
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of BR112017005744A2 publication Critical patent/BR112017005744A2/pt
Publication of BR112017005744B1 publication Critical patent/BR112017005744B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

são fornecidos aqui vírus pichinde geneticamente manipulados que incluem três segmentos genômicos ambissenso. o primeiro segmento genômico inclui uma região codificante que codifica uma proteína z e uma região codificante que codifica uma proteína l rdrp. o segundo segmento genômico inclui uma região codificante que codifica uma nucleoproteína (np) e o terceiro segmento genômico inclui uma região codificante que codifica uma glicoproteína. cada um dentre o segundo e o terceiro segmentos genômicos, opcionalmente, inclui uma região codificante adicional que pode codificar um antígeno ou um marcador detectável. é também aqui fornecido um sistema de genética reversa para fabricar um vírus pichinde geneticamente manipulado, e uma coleção de vetores que podem ser usados para produzir um vírus pichinde geneticamente manipulado. são ainda fornecidos métodos para usar um sistema de genética reversa, e métodos para produzir uma resposta imune em um indivíduo.
BR112017005744-1A 2014-09-22 2015-09-22 "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo" BR112017005744B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053443P 2014-09-22 2014-09-22
US62/053,443 2014-09-22
PCT/US2015/051337 WO2016048949A1 (en) 2014-09-22 2015-09-22 Pichinde virus reverse genetics system and methods of use

Publications (2)

Publication Number Publication Date
BR112017005744A2 true BR112017005744A2 (pt) 2017-12-12
BR112017005744B1 BR112017005744B1 (pt) 2023-11-28

Family

ID=54238628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005744-1A BR112017005744B1 (pt) 2014-09-22 2015-09-22 "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo"

Country Status (12)

Country Link
US (2) US10533159B2 (pt)
EP (1) EP3198008B1 (pt)
JP (1) JP6875274B6 (pt)
KR (1) KR20170057384A (pt)
CN (1) CN107109371A (pt)
AU (1) AU2015321557B2 (pt)
BR (1) BR112017005744B1 (pt)
CA (1) CA2961913A1 (pt)
ES (1) ES2746150T3 (pt)
MX (1) MX2017003694A (pt)
PL (1) PL3198008T3 (pt)
WO (1) WO2016048949A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3198008B1 (en) 2014-09-22 2019-05-29 Regents of the University of Minnesota Pichinde virus reverse genetics system and methods of use
AU2015345080B2 (en) * 2014-11-13 2022-01-27 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
FI3371316T3 (fi) 2015-11-04 2023-01-13 Rokotteita hepatiitti b -virusta vastaan
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
CA3023599A1 (en) * 2016-05-18 2017-11-23 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
WO2022031893A2 (en) * 2020-08-06 2022-02-10 Regents Of The University Of Minnesota Multivalent vaccines against turkey arthritis reovirus
US20240285748A1 (en) 2021-06-21 2024-08-29 Vaxxinova International B.V. Veterinary viral vector
WO2024155646A1 (en) * 2023-01-17 2024-07-25 Regents Of The University Of Minnesota Multivalent vaccines against tuberculosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
AU2008293532B2 (en) * 2007-08-27 2014-08-28 Kineta Four Llc Antiviral drugs for treatment of Arenavirus infection
EP2240201B1 (en) 2007-12-21 2015-04-22 The Government of The United States of America as represented by the Secretary of The Department of Health and Human Services, Centers for Disease Recombinant rift valley fever (rvf) viruses and methods of use
HRP20221475T3 (hr) * 2007-12-27 2023-01-06 Universität Zürich Replikacijski defektni vektori arenavirusa
EP2478103A4 (en) 2009-09-16 2014-02-19 Univ Tulane LASSA VIRUS TYPE PARTICLES AND METHODS OF PRODUCING THE SAME
GB201007790D0 (en) 2010-05-10 2010-06-23 Isis Innovation Compositions
WO2011156273A1 (en) 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
EP3198008B1 (en) 2014-09-22 2019-05-29 Regents of the University of Minnesota Pichinde virus reverse genetics system and methods of use

Also Published As

Publication number Publication date
EP3198008B1 (en) 2019-05-29
AU2015321557B2 (en) 2020-05-14
AU2015321557A1 (en) 2017-04-06
MX2017003694A (es) 2017-10-12
JP6875274B6 (ja) 2021-06-30
US20200165578A1 (en) 2020-05-28
EP3198008A1 (en) 2017-08-02
ES2746150T3 (es) 2020-03-04
JP2017529084A (ja) 2017-10-05
US20170292119A1 (en) 2017-10-12
PL3198008T3 (pl) 2020-03-31
US11993789B2 (en) 2024-05-28
CN107109371A (zh) 2017-08-29
JP6875274B2 (ja) 2021-05-19
WO2016048949A1 (en) 2016-03-31
CA2961913A1 (en) 2016-03-31
US10533159B2 (en) 2020-01-14
BR112017005744B1 (pt) 2023-11-28
KR20170057384A (ko) 2017-05-24

Similar Documents

Publication Publication Date Title
BR112017005744A2 (pt) sistema de genética reversa para vírus pichinde e método de uso
CO2017009676A2 (es) Derivación de información de movimiento a subbloques en la codificación de video
CL2017003377A1 (es) Método combinado para detectar anomalías en un sistema de distribución de agua
BR112019008369A2 (pt) ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CL2020000192A1 (es) Anticuerpos anti-cd8 y usos de estos.
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
CY1119093T1 (el) Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
GB2534810A (en) Passivated cement accelerator
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
BR112017000257A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
CL2017002881A1 (es) Anticuerpos anti-fcrn
BR112018072723A2 (pt) composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito
EA201590692A2 (ru) Система генерирования электроэнергии с использованием водных потоков и способ перемещения такой системы
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
PL396415A1 (pl) Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
PL408649A1 (pl) Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2015, OBSERVADAS AS CONDICOES LEGAIS